Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with bile acid malabsorption (BAM).
Epistemonikos ID: 420a366791ff53f75348a86b2977ff62c4495a6a
First added on: May 09, 2024